Table 2 The correlations of the hs-CRP/HDL-C index with MASLD and advanced liver fibrosis.

From: Nonlinear associations of the hs-CRP/HDL-C index with metabolic dysfunction-associated steatotic liver disease and advanced liver fibrosis in US adults: insights from NHANES 2017–2018

 

Model 1a

P-Value

Model 2b

P-Value

Model 3c

P-Value

MASLD

 hs-CRP/HDL-C

5.39 (3.25, 8.94)

< 0.001

6.09 (3.36, 11.06)

< 0.001

1.82 (1.15, 2.87)

0.010

 Q1

Reference

 

Reference

 

Reference

 

 Q2

2.48 (1.97, 3.12)

< 0.001

2.24 (1.74, 2.89)

0.002

1.83 (1.40, 2.39)

0.001

 Q3

3.88 (3.10, 4.86)

< 0.001

3.75 (2.93, 4.80)

< 0.001

2.45 (1.88, 3.20)

< 0.001

 Q4

6.16 (4.92, 7.70)

< 0.001

7.19 (5.60, 9.23)

< 0.001

3.65 (2.78, 4.80)

< 0.001

 P for trend

< 0.001

 

< 0.001

 

< 0.001

 

Advanced liver fibrosis

 hs-CRP/HDL-C

2.52 (1.54, 4.10)

< 0.001

2.42 (1.49, 3.93)

0.005

1.68 (1.03, 2.75)

0.038

 Q1

Reference

 

Reference

 

Reference

 

 Q2

5.10 (1.94, 13.38)

0.001

4.50 (1.71, 11.85)

0.023

3.44 (1.30, 9.13)

0.013

 Q3

9.21 (3.64, 23.33)

< 0.001

8.39 (3.30, 21.32)

0.002

4.77 (1.84, 12.35)

0.001

 Q4

17.82 (7.19, 44.15)

< 0.001

18.06 (7.26, 44.93)

< 0.001

8.67 (3.39, 22.16)

< 0.001

 P for trend

< 0.001

 

< 0.001

 

< 0.001

 
  1. MASLD metabolic dysfunction-associated steatotic liver disease, Q1 the first quartile group, Q2 the second quartile group, Q3 the third quartile group, Q4 the fourth quartile group.
  2. aModel 1 evaluated the basic correlations of the hs-CRP/HDL-C index with MASLD and advanced liver fibrosis.
  3. bModel 2 corrected for age, gender, race, poverty-to-income ratio, marital status, education level.
  4. cModel 3 further controlled for smoking status, obesity, diabetes mellitus, hypertension, and history of cardiovascular disease, chronic kidney disease, and cancer.
  5. P < 0.05 are bolded.
Back to article page